Xanthine oxidoreductase polymorphisms: Influence in blood pressure and oxidative stress levels

Pharmacogenetics and Genomics

Volumn 17, Issue 8, 2007, Pages 589-596

  Chaves, Felipe J ^a   Corella, Dolores ^a   Blesa, Sebastian ^a   Mansego, Maria L ^a   Marín, Pablo ^a   Portoles, Olga ^a   Sorlí, Jose V ^a   González Albert, Verónica ^a   Tormos, Mari C ^a   García García, Ana B ^a   Sáez, Guillermo ^a   Redon, Josep ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Blood pressure; Hypertension; Oxidative stress; Polymorphism; Xanthine oxidase

Indexed keywords

XANTHINE OXIDASE;

ADULT; ALLELE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT;

BLOOD PRESSURE; CASE-CONTROL STUDIES; DIASTOLE; FEMALE; HAPLOTYPES; HUMANS; HYPERTENSION; MALE; NUCLEOTIDES; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; SYSTOLE; URIC ACID; XANTHINE DEHYDROGENASE;

EID: 34447302065     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000239970.23723.38     Document Type: Article

References (40)

1. De Champlain J, Wu R, Girouard H, Karas M, EL Midaoui A, Laplante MA, Wu L. Oxidative stress in hypertension. Clin Exp Hypertens 2004; 26:593-601.
2. Romero JC, Reckelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34:943-949.
3. Raij L. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 1998; 31:189-193.
4. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension. The role of superoxide anion. Hypertension 1999; 34:539-545.
5. Orie NN, Zidek W, Tepel M. Reactive oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1999; 12:1169-1174.
6. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reactive protein. Hypertension 2002; 39:777-780.
7. Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Saez GT. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41:1096-1101.
8. Newaz MA, Adeeb NN, Muslim N, Razak TA, Htut NN. Uric acid, xanthine oxidase and other risk factors of hypertension and in normotensive subjects. Clin Exp Hypertens 1996; 18:1035-1050.
9. Hille R, Nishino T. Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. FASEB J 1995; 9:995-1003.
10. Li H, Samouilov A, Liu X, Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. Biochemistry 2003; 42:1150-1159.
11. Zhang Z, Naughton D, Winyard PG, Benjamin N, Blake DR, Symons MC. Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun 1998; 249:767-772.
12. Doel JJ, Godber BL, Goult TA, Eisenthal R, Harrison R. Reduction of organic nitrites to nitric oxide catalyzed by xanthine oxidase: possible role in metabolism of nitrovasodilators. Biochem Biophys Res Commun 2000; 270:880-885.
13. Doel JJ, Godber BL, Eisenthal R, Harrison R. Reduction of organic nitrates catalysed by xanthine oxidoreductase under anaerobic conditions. Biochim Biophys Acta 2001; 1527:81-87.
14. Swei A, Lacy F, Delano FA, Parks DA, Schmid-Schonbein GW. A mechanism of oxygen free radical production in the Dahl hypertensive rat. Microcirculation 1999; 6:179-187.
15. Wallwork CJ, Parks DA, Schmid-Schonbein GW. Xanthine oxidase activity in the dexamethasone-induced hypertensive rat. Microvasc Res 2003; 66:30-37.
16. Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H, Matsumoto T. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 2003; 92:81-87.
17. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38:1101-1106.
18. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35:746-751.
19. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003; 107:416-421.
20. Terao M, Kurosaki M, Zanotta S, Garattini E. The xanthine oxidoreductase gene: structure and regulation. Biochem Soc Trans 1997; 25:791-796.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7. JAMA 2003; 289:2560-2572.
22. Brien E, Asmar R, Beilin L, Imai Y, Mallion J-M, Mancia G, et al, on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21:821-848.
23. Muñiz P, Valls V, Perez-Broseta C, Iradi A, Climent JV, Oliva MR, Sáez GT. The role of 8-hydroxy-2-deoxyguanosine in rifamycin-induced DNA damage. Free Radic Biol Med 1995; 18:747-755.
24. Latorre A, Moya A, Ayala FJ. Evolution of mitochondrial DNA in Drosophila subobscura. Proc Natl Acad Sci U S A 1986; 83:8649-8653.
25. Frenkel K, Zong Z, Wei H, Karkiszka J, Patel U, Rashid K, et al. Quantitative high performance liquid chromatography analysis of DNA oxidased in vitro and in vivo. Anal Biochem 1991; 196:126-136.
26. Saez GT, Tormos C, Giner V, Chaves J, Lozano JV, Iradi A, Redon J. Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. Am J Hypertens 2004; 17:809-816.
27. Wong SHY, Knight JA, Hopfer SM, Zaharia O, Leach CN Jr, Sunderman FW Jr. Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin Chem 1987; 33:214-220.
28. Yildirim A, Altinkaynak K, Aksoy H, Sahin YN, Akcay F. Plasma xanthine oxidase, superoxide dismutase and glutathione peroxidase activities and uric acid levels in severe and mild pre-eclampsia. Cell Biochem Funct 2004; 22:213-317.
29. Laakso J, Mervaala E, Himberg JJ, Teravainen TL, Karppanen H, Vapaatalo H, Lapatto R. Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension 1998; 32:902-906.
30. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, et al. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci U S A 1998; 95:4754-4759.
31. Houston M, Estevez A, Chumley P, Aslan M, Marklund S, Parks DA, Freeman BA. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem 1999; 274:4985-4994.
32. Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106:3073-3078.
33. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34:78-84.
34. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997; 30:57-63.
35. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58:87-114.
36. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67:1739-1742.
37. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34:144-150.
38. Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (London) 2004; 1:10.
39. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107:1991-1997.
40. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002; 90:297-304.